Brought to you by:
Increased experience with off-the-shelf TAAA endograft sees reduction in complications but no effect on mortality
Michele Piazza, MD, informed attendees of the 2025 Vascular Annual Meeting (VAM) that increased experience with the E-nside (Artivion) off-the-shelf preloaded inner branch endograft for branched endovascular aneurysm repair (BEVAR) leads to a “significant” reduction in intraprocedural complications, but does not…
Rates of MAE and reintervention following F/BEVAR remain ‘stable,’ Aortic Research Consortium data show
Latest study out of consortium details trends and outcomes after F/BEVAR procedures carried out over an eight-year period under consortium of 10 physician-sponsored IDEs. Despite increasing repair extent and complexity, rates of technical failure, adverse events and reintervention remained “stable”…
Analysis will kickstart conversation on F/BEVAR outcomes
New data presented during Friday’s Plenary Session 6 (10–11 a.m. in the West Building, Skyline Ballroom) will shed light on trends in the adoption of fenestrated and branched endovascular aortic repair (F/BEVAR) outside of Food and Drug Administration (FDA) Investigational…
The top 10 most popular Vascular Specialist stories of January 2024
In January, the most read stories from Vascular Specialist include a U.S. Aortic Research Consortium analysis of F/BEVAR preoperative risk factors in AAAs/TAAAs; a reflection on lessons learnt one year on from BEST-CLI; Southern Vascular’s election of its first female…
Preventing spinal cord ischemia: Novel techniques for direct segmental artery revascularization show promise, WVS 2023 hears
A vascular surgery team from the University of Southern California (USC) in Los Angeles demonstrated the feasibility of multidisciplinary direct revascularization of segmental arteries to prevent spinal cord ischemia (SCI) using novel endovascular or extra-anatomic bypass techniques in high-risk patients…
Future research needed to ‘optimize’ use of imaging technologies during aortic procedures
Imaging technologies in the aortic space will be a key feature of Saturday’s Plenary Session 8 (11:15 a.m. to 12:30 p.m.) in Potomac A/B, with speakers set to share data on Philips’ Fiber Optic RealShape (FORS) technology and Centerline Biomedical’s…
CX Aortic Vienna: Onus on industry to meet clinician desire for devices that function, adapt in long term
The need for vascular companies to home in on developing longer-lasting devices—perhaps even ones that adapt over time to match patients’ changing anatomies—was underscored as part of the Juxtarenal session on day two of the CX Aortic Vienna 2022 Digital Edition (Oct. 24–26).…
Pioneering center reports ‘moderate’ success rate with Fiber Optic RealShape technology in first 50 patients
Vascular surgeons from the medical center that pioneered use of the radiation-lowering Fiber Optic RealShape (FORS) imaging modality reported a 62% technical success rate using the first-generation version of the technology across the first 50 procedures performed. The data were…
Off-the-shelf branched endograft for TAAAs demonstrates safety and effectiveness through two years in both stable, symptomatic patients
Two-year target vessel-related freedom from all-cause and aneurysm-related mortality for an off-the-shelf multibranched endovascular device for the treatment of thoracoabdominal aortic aneurysms (TAAAs) came in at 78.5% and 98.6%, 2022 Vascular Annual Meeting (VAM) attendees heard. The data relate to…
F/BEVAR review reveals less than 20% of patients suffered intraoperative adverse event
A retrospective evaluation of 600 fenestrated or branched endovascular aneurysm repairs (F/BEVARs) for the treatment of complex aneurysms revealed that fewer than one in five patients experienced an intraoperative adverse event, according to a press release announcing study results published…